{"id":"https://openalex.org/W2372907356","doi":null,"title":"Medication of Pulmonary Arterial Hypertension: Novel Endothelin Receptor Antagonists","display_name":"Medication of Pulmonary Arterial Hypertension: Novel Endothelin Receptor Antagonists","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W2372907356","mag":"2372907356"},"language":"en","primary_location":{"id":"mag:2372907356","doi":null,"is_oa":false,"landing_page_url":"http://en.cnki.com.cn/Article_en/CJFDTOTAL-YXLY201306022.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764810485","display_name":"Pharmaceutical and Clinical Research","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Pharmaceutical and Clinical Research","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110780401","display_name":"Zhe Wei","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270815","display_name":"Jiangsu Pharmaceutical Association","ror":"https://ror.org/01c3kcb55","country_code":"CN","type":"nonprofit","lineage":["https://openalex.org/I4405270815"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Zhe Wei","raw_affiliation_strings":["Jiangsu Pharmaceutical Association"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jiangsu Pharmaceutical Association","institution_ids":["https://openalex.org/I4405270815"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5110780401"],"corresponding_institution_ids":["https://openalex.org/I4405270815"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.36498582,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10728","display_name":"Pulmonary Hypertension Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10728","display_name":"Pulmonary Hypertension Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12199","display_name":"Vascular Anomalies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10155","display_name":"Nitric Oxide and Endothelin Effects","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pulmonary-arterial-hypertension","display_name":"pulmonary arterial hypertension","score":1.0},{"id":"https://openalex.org/keywords/endothelin-receptor-antagonists","display_name":"endothelin receptor antagonists","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bosentan","display_name":"bosentan","score":0.8840000033378601},{"id":"https://openalex.org/keywords/ambrisentan","display_name":"ambrisentan","score":1.0},{"id":"https://openalex.org/keywords/macitentan","display_name":"macitentan","score":1.0},{"id":"https://openalex.org/keywords/endothelin-1","display_name":"endothelin-1","score":0.9729999899864197},{"id":"https://openalex.org/keywords/thromboxane-a2","display_name":"thromboxane A2","score":0.8949999809265137},{"id":"https://openalex.org/keywords/vasoconstriction","display_name":"vasoconstriction","score":0.8050000071525574},{"id":"https://openalex.org/keywords/endothelial-cell-proliferation","display_name":"endothelial cell proliferation","score":0.4300000071525574},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.6179999709129333},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6449999809265137}],"concepts":[{"id":"https://openalex.org/C2780263000","wikidata":"https://www.wikidata.org/wiki/Q410789","display_name":"Ambrisentan","level":5,"score":0.9751734733581543},{"id":"https://openalex.org/C2781109936","wikidata":"https://www.wikidata.org/wiki/Q419769","display_name":"Bosentan","level":4,"score":0.9544525742530823},{"id":"https://openalex.org/C144980905","wikidata":"https://www.wikidata.org/wiki/Q24721308","display_name":"Endothelin receptor","level":3,"score":0.7694884538650513},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7395074963569641},{"id":"https://openalex.org/C2776345702","wikidata":"https://www.wikidata.org/wiki/Q390709","display_name":"Endothelin receptor antagonist","level":4,"score":0.6875556111335754},{"id":"https://openalex.org/C2779961880","wikidata":"https://www.wikidata.org/wiki/Q1067506","display_name":"Vasoconstriction","level":2,"score":0.6312509775161743},{"id":"https://openalex.org/C2780930700","wikidata":"https://www.wikidata.org/wiki/Q1128595","display_name":"Pulmonary hypertension","level":2,"score":0.6279188990592957},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5466232895851135},{"id":"https://openalex.org/C519581460","wikidata":"https://www.wikidata.org/wiki/Q207843","display_name":"Nitric oxide","level":2,"score":0.4743465483188629},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.3779710829257965},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3564729392528534},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.21437212824821472}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2372907356","doi":null,"is_oa":false,"landing_page_url":"http://en.cnki.com.cn/Article_en/CJFDTOTAL-YXLY201306022.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764810485","display_name":"Pharmaceutical and Clinical Research","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Pharmaceutical and Clinical Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W126061631","https://openalex.org/W2068832783","https://openalex.org/W1995521712","https://openalex.org/W2358343020","https://openalex.org/W2139833219","https://openalex.org/W4417076138","https://openalex.org/W2943932948","https://openalex.org/W2009411008","https://openalex.org/W4386291415","https://openalex.org/W2003487219"],"abstract_inverted_index":{"In":[0],"recent":[1],"years,drugs":[2],"for":[3],"the":[4,13],"treatment":[5],"of":[6,15,41],"pulmonary":[7],"arterial":[8],"hypertension":[9],"aimed":[10],"at":[11],"regulating":[12],"balance":[14],"endogenous":[16],"vasoconstriction(such":[17],"as":[18],"endothelin-1,thromboxane":[19],"A2)":[20],"and":[21,24,37,46],"proliferation":[22],"medium(prostaglandins":[23],"nitric":[25],"oxide)":[26],"were":[27],"rapidly":[28],"developed.":[29],"Currently":[30],"available":[31],"endothelin":[32],"receptor":[33],"antagonists":[34],"including":[35],"bosentan,ambrisentan":[36],"macitentan,with":[38],"clinical":[39],"advantages":[40],"minor":[42],"system":[43],"side":[44],"effects":[45],"oral":[47],"administration,are":[48],"reviewed":[49],"in":[50],"this":[51],"article.":[52]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}